VistaGen Therapeutics Inc

NASDAQ:VTGN   10:59:10 AM EDT
0.16
+0.01 (+6.51%)
Products, Regulatory

Vistagen To Proceed With Palisade-2 Phase 3 Clinical Trial Of Ph94b In Social Anxiety Disorder Following Interim Analysis

Published: 09/08/2022 12:09 GMT
VistaGen Therapeutics Inc (VTGN) - Vistagen to Proceed With Palisade-2 Phase 3 Clinical Trial of Ph94b in Social Anxiety Disorder Following Interim Analysis.
Vistagen Therapeutics Inc - Topline Data for Palisade-2 Trial Expected in First Half of 2023.
Vistagen Therapeutics Inc - Independent Biostatisticians Recommend Continuing Palisade-2 Without Any Changes.
Vistagen Therapeutics Inc - No Severe Or Serious Adverse Events Were Reported for Ph94b in Palisade-1 Or Palisade-2 Or in Other Clinical Trials.